Skip to content
Peptigraph home

REDEFINE 2: CagriSema Phase 3 trial (NCT05394519)

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
1,200
actual
Start
1 Feb 2023 (actual)
Primary completion
28 Jan 2025 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT05394519 study arms
ArmTypeInterventionsDescription
CagriSemaExperimentalDrug: Cagrilintide; Drug: SemaglutideCagrilintide + semaglutide once weekly
PlaceboPlacebo comparatorDrug: Placebo cagrilintide; Drug: Placebo semaglutidePlacebo cagrilintide + semaglutide once weekly
Endpoints

Primary endpoint

NCT05394519 primary outcomes
MeasureTime frame
Relative change in body weightFrom baseline (week 0) to end of treatment (week 68)
Achievement of greater than or equal to (≥) 5% weight reductionFrom baseline (week 0) to end of treatment (week 68)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05394519 secondary outcomes
MeasureTime frame
Achievement of ≥ 20% weight reductionFrom baseline (week 0) to end of treatment (week 68)
Relative change in body weightFrom baseline (week 0) to week 20
Change in waist circumferenceFrom baseline (week 0) to end of treatment (week 68)
Change in Glycated Haemoglobin (HbA1c)From baseline (week 0) to end of treatment (week 68)
Change in Systolic Blood Pressure (SBP)From baseline (week 0) to end of treatment (week 68)
Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function scoreFrom baseline (week 0) to end of treatment (week 68)
Change in Short Form-36 Version 2.0 Health Survey Acute (SF-36v2 Acute) Physical Functioning scoreFrom baseline (week 0) to end of treatment (week 68)
Change in body weightFrom baseline (week 0) to end of treatment (week 68)
Change in body mass index (BMI)From baseline (week 0) to end of treatment (week 68)
Improvement in weight category (BMI, underweight below 18.5, normal weight 18.5 to below 25, overweight 25.0 to below 30, obesity class I 30 to below 35, obesity class II 35 to below 40, obesity class III above 40)From baseline (week 0) to end of treatment (week 68)
Achievement of HbA1c less than or equal to (≤) 6.5%At end of treatment (week 68)
Change in Fasting Plasma Glucose (mmol/L)From baseline (week 0) to end of treatment (week 68)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

The REDEFINE 2 paper in adults with obesity and type 2 diabetes

Adults with a BMI of 27 or more and HbA1c of 7 to 10% were assigned 3:1 to once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo for 68 weeks, alongside lifestyle intervention.[2]

Body weight changed by -13.7% with the combination and -3.4% with placebo, an estimated difference of -10.4 percentage points (95% CI -11.2 to -9.5).[2]

An HbA1c of 6.5% or less was reached by 73.5% of the combination group and 15.9% of the placebo group.[2]

Gastrointestinal adverse events were reported by 72.5% of the combination group and 34.4% of the placebo group.[2]

Sources

  1. 1Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026

Found an error? Report a correction.